Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Number of employees : 105 794 people.
2019 2020 Delta Innovative Medicines 37 479.50 79.4% 36 618.10 80.2% -2.3% Sandoz 9 670.50 20.5% 9 053.87 19.8% -6.38%
CHF in Million
2020 United States 15 472.10 33.9% Europe 10 282.50 22.5% Asia/Africa/Australasia 4 544.77 10% Germany 4 240.66 9.3% Canada and Latin America 3 042.05 6.7% Japan 2 631.87 5.8% China 2 415.05 5.3% France 2 292.10 5% Switzerland 750.89 1.6%
CHF in Million
Shareholders Novartis AG (CH0012005267) Novartis AG (US) Novartis AG (CH0038459415) Novartis AG (ARDEUT112521)
Name Equities % Novartis AG 95,088,390
3.91% Sandoz Family Foundation 89,135,960
3.66% The Vanguard Group, Inc. 58,449,408
2.40% UBS Asset Management Switzerland AG 56,764,402
2.33% Norges Bank Investment Management 56,446,398
2.32% Novartis Foundation For Employee Participation 49,094,512
2.02% Wellington Management Co. LLP 43,097,437
1.77% Credit Suisse Asset Management (Schweiz) AG 32,345,192
1.33% Zürcher Kantonalbank (Investment Management) 22,916,663
0.94% Dodge & Cox 22,514,870
0.92%
Name Equities % Dodge & Cox 29,265,900
1.20% PRIMECAP Management Co. 19,061,650
0.78% Loomis, Sayles & Co. LP 18,939,445
0.78% Fisher Asset Management LLC 10,305,029
0.42% Aristotle Capital Management LLC 8,127,686
0.33% Managed Account Advisors LLC 7,003,964
0.29% Franklin Mutual Advisers LLC 6,673,034
0.27% UBS Financial Services, Inc. 4,412,186
0.18% Charles Schwab Investment Advisory, Inc. 4,398,928
0.18% Boston Partners Global Investors, Inc. 4,384,549
0.18%
Name Equities % AQR Capital Management LLC 5,116
- LUKB Expert Fondsleitung AG 35,714
- Deka Investment GmbH 7,129
- Majedie Asset Management Ltd. 474
- Neuberger Berman Investment Advisers LLC 154
-
Name Equities % Gemmer Asset Management LLC 140
0.0000%
Name Equities % Valuation
NOVARTIS INDIA LIMITED (500672) 17,450,680
70.7%
182,005,706 USD
SOMALOGIC, INC. (SLGC) 10,422,469
5.75%
121,317,539 USD
MOLECULAR PARTNERS AG (MOLN) 1,739,130
5.39%
33,916,600 USD
XOMA CORPORATION (XOMA) 539,131
4.77%
11,240,881 USD
GENSIGHT BIOLOGICS S.A. (SIGHT) 1,390,487
3.02%
8,791,813 USD
AYALA PHARMACEUTICALS, INC. (AYLA) 698,777
5.01%
5,946,592 USD
OXURION NV (OXUR) 2,177,226
5.57%
4,496,320 USD
TSCAN THERAPEUTICS, INC. (TCRX) 916,101
4.92%
4,122,455 USD
TSCAN THERAPEUTICS, INC.
863,045
8.63%
3,883,703 USD
BIOLINERX LTD. (BLRX) 4,999,995
0.70%
695,599 USD
- Primary listing
- SMI / FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
- Bloomberg Code :
- Reuters Code :
NOVN.S
- Datastream Code :
S:NOVS
Company contact information
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Basel-Stadt
Phone : +41 61 324 11 11
Fax : +41 61 324 80 01
web site :
http://www.novartis.com
Factbox-GSK's consumer health business
NOVARTIS AG
Sector Other Pharmaceuticals
Connections : Novartis AG
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
